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ABSTRACT
The Role of PTIP in Breast Cancer
In the U.S., breast cancer comprises about 30% of all cancer cases (excluding skin cancer)
in women. Such a high incidence makes breast cancer a significant health concern, but
our understanding of the molecular and cellular mechanisms of this disease is still limited.
Growing evidence suggests that the development of human breast cancer may involve
epigenetics, which attributes changes in phenotype to mechanisms other than changes in
the DNA sequence itself. Histones as the chief proteins of chromatin work on gene
expression, and methylation of histone 3 lysine 4 (H3K4) results in transcriptional
activation. Lately, Paired box (Pax) trans-activation domain-interacting protein (PTIP),
part of the H3K4 methyl-transferase complex, has been identified as a novel regulator of
histone methylation. In this study, we hypothesize that PTIP plays a role in the epigenetic
regulation of breast cancer cell growth. Two human breast cancer cell lines MCF-7
(adeno carcinoma) and T47D (ductal carcinoma) are used in this study. To test our
hypothesis, we have first determined the PTIP mRNA expression level in MCF-7 and
T47D cells by reverse transcription-polymerase chain reaction (RT-PCR) and the PTIP
protein level by Western blot. We have also determined PTIP’s sub-cellular localization
in MCF-7 and T47D cells by immunofluorescence assay. In addition, we have knocked
down and over-expressed PTIP. In other words, we reduced and increased the expression
of PTIP in MCF-7 and T47D cells through siRNA (small interference RNA) and ectopic
over-expression respectively. We then examined the effects of PTIP knockdown and
PTIP over-expression on MCF-7 and T47D cell growth. As a result, we found that PTIP
xi

knockdown in MCF-7 cells results in an increase of cell proliferation. The information
collected from this study will allow us to comprehend PTIP’s role in breast cancer cell
growth and contribute to our understanding of the epigenetic basis of human breast
cancer.

Key Words: breast cancer, PTIP, epigenetics, histone methylatio
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Chapter One
Introduction
Breasts are located symmetrically in the left and right sides of the upper ventral
region. They are composed of glands, vessels, adipose and fibrous tissues. For women,
the breast is a secondary sex character and produces milk to children during lactation.
Breast cancer is the most common cancer in women and it is caused by malignancy
invasion that destroys the normal breast tissue. There are some factors affecting the
occurrence of breast cancer, such as long term stimulus of estrogen, virus, heredity,
nutrition, and psychological stress.
In the United States, cancer is a critical health issue that causes death in one of
every four people. Breast cancer, as one of the four major cancers, accounts for about 34%
of total cancers in women [1]. From 2010 to 2020, the largest increase of medical cost for
women is predicted to be caused by breast cancer. The rate of cost increase would be
around 32% [2]. For women between 20 and 59 years old, breast cancer is the leading
cause in cancer death. In 2012, there are 226,870 new breast cancer cases, representing
29% of total new female cancer cases, predicted among women [1].
Breast cancer, taking up about 34% of total female cancers, is the most common
cancer in the United States [3]. However, our understanding of breast cancer is still
limited. Recently, it has been found that cancers are related to epigenetics, which
attributes changes in phenotype to mechanisms other than changes in the DNA sequence
itself, such as histone modification [4].
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Histone modification plays various functions in regulating genome functions,
such as, in DNA damage repair and gene transcription. Histone methylation is one of the
histone modifications and is linked to transcriptional regulation. Methylation of specific
lysine residues of histone, for example, lysine 4 on histone 3 (H3K4), is associated with
transcriptional activation [5].
Paired box (Pax) trans-activation domain-interacting protein (PTIP), part of the
H3K4 methyl-transferase complex, has been identified as a novel regulator of histone
methylation [6]. In this study, hypothesize that PTIP plays a role in the epigenetic
regulation of breast cancer cell growth. Two human breast cancer cell lines MCF-7
(adeno carcinoma) and T47D (ductal carcinoma) were used as the studying model.
.
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Objectives
1. Determine the gene expression of PTIP in breast cancer cell lines MCF-7 and
T47D.
2. Determine the protein expression of PTIP in breast cancer cell lines MCF-7 and
T47D.
3. Determine the sub-cellular localization of PTIP in breast cancer cell lines MCF-7
and T47D.

4. Determine the functions of PTIP in breast cancer cell lines MCF-7 and T47D.
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Specific Aims
Specific Aim 1: Determine the gene expression of PTIP in breast cancer cells.
The RT-PCR technique was used to determine the gene expression of PTIP in
MCF-7 and T47D breast cancer cells.
Specific Aim 2: Determine the protein expression of PTIP in breast cancer cells.
The protein expression of PTIP in MCF-7 and T47D cells was evaluated by
Western blot.
Specific Aim 3: Determine the subcellular localization of PTIP in breast cancer
cells.
The sub-cellular localization of PTIP in MCF-7 and T47D cells was examined by
immunofluorescence.
Specific Aim 4: Determine PTIP function in breast cancer cells.
First, the protein level of PTIP in MCF-7 and T47D cells was knocked down by
RNA interference (RNAi). Second, ectopic PTIP was overexpressed in MCF-7 and T47D
cells. Third, we investigated the effects of PTIP knockdown and PTIP overexpression on
cell proliferation.
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Chapter Two
Review of Literature

Part I: Breast cancer and breast cancer cells
Part II: Epigenetic regulation and histone methylation
Part III: the PTIP gene

Part I: Breast cancer and breast cancer cells

Figure 1. Estimated US cancer cases in 2011. http://www.cancer.org
In the U.S., as the most common cancer in women, breast cancer accounts for 30%
or so of all female cancers [3]. It is estimated that there will be 226, 870 new breast
cancer cases which make up 29% in 2012 [1]. In addition, the cancer treatment cost in
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2010 was 12.57 billion dollars but in 2020 is predicted to be 157.77 billion dollars. The
biggest increase, 32%, of medical spending was for breast cancer treatment for women
[2]. However, our understanding of this disease is still limited. Public health data (PHD)
pointed out that there were more than one million women who died from breast cancer
each year [7]. It is significant to understand the cellular and molecular mechanisms of
breast cancer so that we can develop better treatment for women with breast cancer.
The breast cancer cell lines are limited, and just a few of them are used for
research, such as MCF-7 (adeno carcinoma) and T47D (ductal carcinoma). Also, a large
percentage of available research reports on breast cancer have used the cell lines MCF-7
and T47D [8] [9]. Accordingly, we used MCF-7 and T47D in this study.

Part II: Epigenetic regulation and histone methylation
Epigenetics attributes changes in the phenotype to mechanisms other than changes
in the DNA sequence itself, such as histone methylation and DNA methylation [10]. On a
molecular level, epigenetics can activate expression of specific genes without changing
the DNA structure. In addition, gene paramutation is an example of epigenetic
inheritance [11].
Growing evidence shows that epigenetics is related to human cancers [12]. For
example, regulating the tumor suppressor genes by histone modification influences the
development of cancer [13].
Histones, or proteins in the nucleus, function on gene expression. Histones
compact the DNA about 3-fold the remaining compaction is due to folding of chromatin
[14]. There are two types of histones, core histones (H2A, H2B, H3 and H4) and linker
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histones (H1 and H5) [15]. Several well-known histone modifications are lysine
methylation (me), arginine methylation, lysine acetylation (ac) and
Serine/Threonine/Tyrosine phosphorylation [16]. Histone lysine modifications, such as
H3K4me1, H3K4me3, H3K9me1, H3K9ac, H3K14ac, H3K27me1, H3K79me1,
H3K79me2, H3K79me3, H3K20me1, and H2BK5me1, can activate gene transcription.
On the other hand, H3K9me2, H3K9me3, H3K27me2, H3K27me3, H3K79me3 and
H2BK5me3 can repress gene transcription [17] [18] [19] [20] [21].

Figure 2. Histone and DNA. http://en.wikipedia.org/wiki/File:Nucleosome_structure.png
H3K4me, the example of histone methylation, plays a role in transcriptional
activation [22]. Yeast SET1 and mammalian mixed lineage leukemia (MLL) can
methylate H3K4. MLL, the gene related to aggressive acute leukemia (ALL) [23], can
activate the transcription of oncogenes and consequently cause leukemias and cancers.
[24] [25]. With this regard, H3K4me is associated with cancer development.
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Part III: the PTIP gene
PTIP, Pax transactivation-domain interacting protein [26], is component of the
histone methyltransferase (HMTase) complex which also contains MLL3 or MLL4 [27]
[28] [29]. Recent studies have shown that PTIP is a novel regulator of H3K4 methylation
[20] [31]. Additionally, because H3K4me can activate gene transcription, PTIP has been
thought to be involved in transcriptional activation.

Figure 3. A hypothetical model of PTIP-mediated epigenetic regulation of breast cancer.
HMT, Histone methyltransferase; H3K4me, histone 3 lysine 4 mono-, di-, or
trimethylation; PAX2, paired homeobox 2; PRE, Pax2-response element; ORF, open
reading frame.

Paired homeobox 2 (Pax2) engages PTIP to bind to the Pax2 response element
(PRE). Subsequently, PTIP attracts the histone methyltransferase (HMT) complex which
contains MLL (MLL3/MLL4). MLL methylates H3K4, and then H3K4me activates gene
transcription. All in all, PTIP activates gene expression by epigenetic regulation. MLL is
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known to activate oncogenes during cancer development. Thus, through functional
association with MLL, PTIP may activate oncogenes in breast cancer cells.
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Chapter Three
Methods and Materials
Cell culture (MCF7 and T47D)
Complete culture medium: Add 50ml of fetal bovine serum and 5ml of penicillinstreptomycin to 500ml of base medium.
Passage cells when they are 70-80% confluent of the plates.
1)

Remove and discard culture medium.

2)

Briefly rinse the cell layer with 5-10ml of PBS to remove all traces of serum
which contains trypsin inhibitors.

3)

Add 1.5ml of Trypsin-EDTA solution to the plate, and incubate the plate at 37°C
for 3-10 minutes to allow cells to detach. Do not agitate the cells by hitting or
shaking the pate while waiting for the cells to detach.

4)

Add 5 ml of DMEM and aspirate cells by gently pipetting, and then transfer cell
suspension to a 15ml tube.

5)

Centrifuge for 5 minutes at 1400rpm.

6)

Discard supernatant, resuspend cells in 5ml of medium, and add appropriate
aliquots of the cell suspension to a new culture plate. Add 10ml medium to a new
plate before add the cell suspension.

Viable cell counting
1)

Add 10µl of cell suspension and 10 λ of Trypan Blue to a 1.5ml tube and mix.
Trypan Blue stains non-viable (dead) cells.
10

2)

Place 10 λ of the mixture in both wells of a hemocytometer, make sure the entire
surface of the rectangular grid of the hemocytometer is covered.

3)

Count viable cells in central squares on both sides of the hemocytometer using a
hand counter. If cells are on the border outlining each square, count only the cells
on the top and left border of the square.

4)

Calculate cell concentration:
# of cells / square × 2 × 104 = ? cells / ml

Thaw frozen cells
1)

Thaw the vial by gentle agitation in a 37°C water bath, keep the O-ring and cap
out of the water to reduce the possibility of contamination. Thawing should be
rapid, less than 2 minutes.

2)

Remove the vial from the water bath as soon as the contents are thawed and
decontaminate by spraying with 70% ethanol. Transfer the vial contents to a
culture dish containing 10ml warm medium.

3)

Let cells sit overnight at 37°C in the incubator, and then change medium to get rid
of DMSO.

Freeze cells
1)

Harvest cells from plates with Trypsin-EDTA solution.

2)

Resuspend cells in cryoprotectant medium (complete culture medium
supplemented with 5% DMSO), final cell concentration is 1~3 × 106 / ml.

3)

Add 1 ml cell suspension to each vial carefully.
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4)

Place vials at -20°C for 2 hours, and then put vials into -80°C freezer overnight.

5)

The second day, transfer vials into a LN2 container for storage.

RNA Extraction from Cultured Cells
1)

Remove medium from cultured cells.

2)

Add TRI Reagent to homogenize cells, incubate the plate for 5 minutes at room
temperature.

3)

Add TRI Reagent 1ml to each 10cm culture dish, 0.5ml to each well of 6-well
plate. Homogenized cells can be stored at -70°C, at least one month.

4)

Add 200 λ of chloroform to 1ml of homogenized cells or 100 λ to 0.5ml of
homogenized cells, vortex for 15 seconds, incubate the mixture for 10 minutes at
room temperature.

5)

Centrifuge for 10 minutes at 12,000rpm at 4°C.

6)

Transfer the aqueous phase to a fresh tube carefully.

7)

Add 500 λ of 2-propanol for original 1ml of homogenized cells or 250 λ for
original 0.5ml of homogenized cells, vortex for 10 seconds, incubate for 10
minutes at room temperature.

8)

Centrifuge for 10 minutes at 12,000rpm at 4°C.

9)

Discard supernatant carefully by pipetting.

10)

Wash the pelleted RNA with 500 λ of 70% ethanol in nuclease-free water.

11)

Air dry RNA pellet for 3-10 minutes.

12)

Dissolve RNA in 10-30 λ of nuclease-free water for 5 minutes at room
temperature, and then put on ice.
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13)

Determine RNA concentration.

RNA Reverse Transcription (RT) with Advantage RT-for-PCR Kit
1)

Make a mixture as follows:
RNA

1 µg

Random primer

1λ

Nuclease-free water

?λ

Total

13.5 λ

2)

Mix and spin down once.

3)

Heat for 2 minutes at 70°C.

4)

Quench rapidly on ice.

5)

Add components as follows:
5 × reaction buffer

4λ

dNTP mix (10mM each)

1λ

MMLV reverse transcriptase

1λ

Nuclease-free water

0.5 λ

Total

6.5 λ

6)

Mix and spin down, incubate for two hour at 42°C.

7)

Spin down the contents of the tube.

8)

Dilute cDNA to a final volume of 100 λ by adding 80 λ nuclease-free water.

9)

Vortex and spin down.

10)

Use 3 µl of diluted cDNA for each 30-µl PCR reaction:
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10 × reaction buffer

3λ

dNTP mix (10mM each)

0.6 λ

Taq

0.6 λ

Primer

0.6 λ

DNA sample

3λ

Nuclease-free water

22.2 λ

Total

30 λ

Protein Extraction from Cultured Cells
1)

Remove cultured medium, add 5ml PBS to rinse the cells.

2)

Add 1.5ml Trypsin-EDTA solution to the plate and place it for 5 minutes at 37°C.

3)

Add 5ml medium, remove the cells to a 15ml tube, spin down for 5 minutes.

4)

Resuspend cells in 5ml cold PBS, centrifuge for 5 minutes at 1400rpm at room
temperature.

5)

Remove PBS carefully by pipetting.

6)

Add the IP lysate buffer 90 λ and proteinase inhibitor 10 λ, mix with pipette, on
ice.

7)

Transfer all mixture to a 1.5ml tube, incubate for 30 minutes on ice.

8)

Centrifuge for 10 minutes at 12,000 rpm at 4°C.

9)

Transfer supernatant (proteins) to a new 1.5ml tube, and keep the tube on ice.

10)

Determine protein concentration.

11)

Stored at -20°C.
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Western blot
1)

Add 100µg=0.1mg protein sample and 2λ 6×R buffer to a 500λ tube.

2)

Heat tubes at 100°C for 3 minutes.

3)

Spin down once.

4)

Load 10 λ protein marker and protein samples into the gel. Add 2-3 λ 6×R buffer
to each blank wells.

5)

Add running buffer (1×SDS), run at 80V for 10 minutes, then at 100V for 1 hour.

6)

Add transfer buffer to 3 boxes. Put 2 pieces of sponge and 2 pieces of blot paper
in a box. Put 1 membrane in a small box (can’t touch the membrane by hands).

7)

Remove the gel from glass plates and place the gel in transfer buffer.

8)

Wash membrane with methanol one time (20 seconds) and D-water two times
(shake 2 minutes for the second time).

9)

Make a sandwich on the transfer machine of sponge, blot paper, membrane, gel,
blot paper, sponge, make sure to add transfer buffer between each component of
the sandwich and roll out any air bubbles at each step.

10)

Add transfer buffer to a transfer box, run at 100V for 65 minutes.

11)

Shake the membrane in blocking solution (0.75g 0.5% milk in 20ml 1×TBST) for
1 hour.

12)

Discard blocking buffer, then wash the membrane with 1×TBST one time.

13)

Add 1.5λ primary antibody and 3000 λ 1×TBST, shake for 1 hour.

14)

Wash the membrane with TBST 4×5 minutes.

15)

Add 0.6λ secondary antibody and 4000 λ 1×TBST, shake for 1 hour.
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16)

Wash the membrane with TBST 4×5 minutes.

17)

Develop picture using ECL color solution.

Immunofluorescence
1)

Culture cells in glass coverslips and place coverslips in 3.5cm Petri dish.

2)

Wash coverslips with PBS one or two times.

3)

Fix cells with 1 ml 2% formaldehyde for 15 minutes (Don’t shake).

4)

Wash coverslips with PBS 2×5 minutes.

5)

Optional: add 0.1% Trition X-100 to break cell membrane for 5 minutes.

6)

Wash coverslips with PBS 2×5 minutes.

7)

Block nonspecific binding by incubating 1 ml blocking solutions for 30 minutes
(0.3g BAS in 10ml PBS).

8)

Put a piece of parafilm on a plate, also put a piece of kimwipe with water near
parafilm in order to keep moist.

9)

Add primary antibody and incubate 1 hour (antibody:1×TBST=1:200).

10)

Wash coverslips with PBS 3×5 minutes.

11)

Add secondary antibody and incubate 1 hour (antibody:1×TBST=1:500).

12)

Wash coverslips with PBS and DAPI (5λ) 1 time, with PBS 2×15 minutes.

13)

Add coverslips to slides and seal with nail polish.

14)

Observe with fluorescent microscope.

Amplification of the flag-mPTIP plasmid and transform the plasmids into the
competent cells

16

1)

Add 8g LB Agar to 200ml D-water and auto-clave.

2)

Add 10ul ampicillin (50μg/ml, Amp) in LB Agar solution.

3)

Add 100 λ E.coli competent cells and 2 λ flag-mPTIP plasmid to each tube.
Incubate on ice for 30 minutes. Then incubate in 42°C water bath for 30-40
seconds. Lastly, incubate on ice for 5 minutes.

4)

Add 500 λ S.O.C medium to each tube.

5)

Shake at 37°C for 1 hour.

6)

Spread 100 λ competent cells on each Amp LB Agar plate.

7)

Invert the plate and place in incubator at 37°C overnight.

8)

Add 5ml LB Broth and 1.25 λ Amp (200μg/ml) to each 13ml tube. Shake
overnight.

9)

Transfer 1.5ml LB Broth to 1.5ml tube. Centrifuge the tubes at 12,000rmp for 5
minutes.

10)

Remove the supernatant and then add 1.5ml LB Broth to the tube.

11)

Centrifuge the tubes and remove the supernatant.

12)

Repeat the step 10 and 11.

13)

Add PBS to wash the cells.

14)

Centrifuge and remove the supernatant.

15)

Plasmid extraction was done by a Qiagen kit.

Transfer the flag-mPTIP plasmids to cultured cells (overexpression)
1)

Prepare 2×105-6×105 adherent cells/well (6-wells plate).

2)

Remove the old medium. Add 1.5ml DMEM medium to each well.

17

3)

Prepare 2 tubes: add 4 λ DNA (the flag-mPTIP plasmid) and 250 λ DMEM
medium to tube 1; add 10 λ transfer reagent (lipofectamine 2000) and 250 λ
DMEM medium to tube 2 (The volume is for each well).

4)

Combine tube 1 and 2, then incubate for 20 minutes at room temperature.

5)

Add 514 λ of the mixed solution to each well.

6)

Culture cells for 2 days. After that, Western blot or MTT assay was carried out.

Transfer siRNA-PTIP to cultured cells (knockdown)
1)

Prepare 2×105-6×105 adherent cells/well (24-wells plate).

2)

Remove the old medium. Add 1.5ml serum-free DMEM medium to each well.

3)

Prepare 2 tubes: add 10λ siRNA-PTIP and 190λ serum-free DMEM medium to
tube 1; add 5λ transfer reagent and 195λ serum-free DMEM medium to tube 2
(The volume is for each well).

4)

Combine tube 1 and 2, then incubate for 20 minutes at room temperature.

5)

Add 400 λ the mixed solution to each well.

6)

Culture cells for 2 days. After that, Western blot or MTT assay was performed.

MTT assay (overexpression or knockdown)
1)

After overexpression or knockdown as described above, the cells are ready for
further experiment.

2)

Remove old medium, and add 2ml MTT solution to each well (24-wells plate).

3)

Incubate at 37°C for 3 hours.

4)

Remove MTT solution and add 1ml SMDO solution to each well.
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5)

Shake for 5 minutes.

6)

Determine the cell proliferation by a plate reader machine (BIO-RAD) on day 1,
day 2 and day 3.
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Chapter Four
Results
1. The PTIP gene is expressed in MCF-7 and T47D breast cancer cells.
MCF-7

T47D

Size:311bp

Size:300bp

Figure 4. Gene expression of PTIP in MCF-7 and T47D human breast cancer cells
The gene expression of PTIP in MCF-7 and T47D was determined by RT-PCR.
The expected size of the PCR product is 311bp. The result indicates that PTIP is
expressed in these two human breast cancer cell lines.
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2. The PTIP protein is expressed in MCF-7 and T47D breast cancer cells.

Figure 5. Left, protein expression of PTIP in MCF-7 and T47D human breast cancer cells;
right, protein expression of GAPDH in MCF-7 and T47D human breast cancer cells.
The protein expression of PTIP in MCF-7 and T47D was determined by Western
Blot. We ordered anti-PTIP from Sigma and got the size of PTIP protein was 120KD.
Our result reveals that PTIP is expressed in these two human breast cancer cell lines on
the protein level.
In addition, the protein of GAPDH was examined by Western Blot in order to
serve as the loading control. The expression level of GAPDH in MCF-7 human breast
cancer cells is almost the same as that in T47D human breast cancer cells. The protein
molecular weight of GAPDH is about 37KD.
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3. PTIP is localized in the nucleus of MCF-7 and T47D breast cancer cells.
MCF-7

Figure 6-1. Subcellular localization of PTIP in MCF-7 human breast cancer cells by
immunofluorescent assay. Magnification: 1220×20.
Left panel: phase contrast; middle panel: DAPI staining (blue); right panel: PTIP staining
(green).
T47D

Figure 6-2. Subcellular localization of PTIP in T47D human breast cancer cells by
immunofluorescent assay. Magnification: 1220×20.
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Left panel: phase contrast; middle panel: DAPI staining (blue); right panel: PTIP staining
(green).
The phase contrast images reveal cellular morphology. The blue images show the
location of nuclei and the green pictures disclose the location of PTIP. After merging the
phase contrast, blue and green images together, we determine that the subcellular
localization of PTIP in MCF-7 and T47D human breast cancer cells is in the nucleus, not
in the cytoplasm. The result suggests that PITP might function in the nucleus to regulate
gene expression. Furthermore, the green signal in MCF-7 cells is much stronger than that
in T47D cells, suggesting that PTIP is expressed at a higher level in MCF-7 cells than in
T47D cells.
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4. Amplification of the flag-mPTIP plasmid in E. coli

Figure 7. Gel electrophoriesis of the flag-mPTIP plasmid.
E.coli was transformed by the flag-mPTIP plasmid. Subsequently, a single colony was
picked up for plasmid amplification and purification. Gel electrophoresis was used to
detect the purified DNA. We observed a single band of 9.2 kb, which is the expected size
of the flag-mPTIP plasmid.
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5. GFP plasmid DNA transfection

Figure 8. Transfection of the GFP plasmid in MCF-7 and T47D human breast cancer
cells. Magnification: 1220×40.

Because GFP is easy to be transferred into mammalian cells and also is
convenient to be monitored by a fluorescent microscope, we used GFP to practice the
transfection skill.
The top row represents the breast cancer cell line MCF-7 and the bottom row
represents the breast cancer cell line T47D. The gray pictures (fluorescence) show cells
morphology. The green pictures (fluorescence) illustrate GFP signal.
On the top row of MCF-7 cells, for example, there are two cells at the left-top
corner of the gray picture and two green dots at the left-top corner of the green picture.
The transfection ratio for MCF-7 cells is more than 90%. The bottom row is T47D cells.
The cell morphology is not very clear, but we still can see a larger cell at the right-top
25

corner and a large green dot at the same location in the green picture. The transfection
ratio for T47D cells is about 70%.

26

6. Western blot of ectopically expressed flag-mPTIP

Figure 9. Protein expression of the flag-mPTIP plasmid in MCF-7 and T47D breast
cancer cells. C, control without the flag-mPTIP plasmid; T, transfection with the flagmPTIP plasmid.
After transfection, cell lysates were prepared for Western blot. We did not detect
a specific band of flag-mPTIP (the expected size is about 120kD). Instead, many
nonspecific bands were noticed.
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7. The protein expression of PTIP in MCF-7 human breast cancer cells
(control/knockdown)

Figure 10. Left, Protein expression of PTIP in MCF-7 human breast cancer cells; right,
protein expression of GAPDH in MCF-7 human breast cancer cells (knockdown/control).
Small interfering RNA (siRNA) binds to its target mRNA and stops translation.
Thus, siRNA is a powerful approach to knock down protein expression of a specific gene.
We used this approach in an attempt to knock down PTIP in MCF-7 cells and T47D cells.
The protein expression of PTIP control and PTIP knockdown in MCF-7 was
determined by Western blot (Figure 10, left panel). PTIP (about 120KD) was detected in
both PTIP control and knockdown samples.
The protein of GAPDH was examined in order to work as the loading control
(Figure 10, right panel). The expression of GAPDH in PTIP control cells is almost the
same as that in PTIP knockdown cells. The protein molecular weight of GAPDH is about
37KD.
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PTIP knockdown

55.74%

PTIP control

44.26%

GAPDH (PTIP knockdown cells)

51.80%

GAPDH (PTIP control cells)

48.20%

Effect (knockdown)

1.076

Effect (control)

0.918

Effect=PTIP/GAPDH

Table 1. Western blot quantification by Image J.
By using the software ImageJ to quantify Western blot results, we found that the
protein expression of PTIP in the knockdown cells is higher than that in the control cells.
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8. MTT cell proliferation assay (PTIP knockdown)

Day 1
MCF-7
control
T47D
control

Average

Average Effect

1.329 0.806 0.699

MCF-7
0.945 knockdown 1.488 0.695 0.516

0.900

0.952

2.282 1.716 2.255

T47D
2.084 knockdown 2.044 2.532 2.463

2.346

1.126

MCF-7
control

1.089

1.34 1.499

MCF-7
1.309 knockdown 1.277 1.482 1.209

1.323

1.010

T47D
control

2.513 2.014 1.945

T47D
2.157 knockdown 1.637 1.039 1.898

1.525

0.707

MCF-7
control

0.147 0.141

0.06

MCF-7
0.116 knockdown 2.233 0.527 0.826

1.195 10.305

T47D
control

1.711 0.967 2.168

T47D
1.615 knockdown 2.098 1.596 2.348

2.014

Day 2

Day 3

Effect=average knockdown/average control

Table 2. MTT assay for PTIP knockdown in MCF-7 and T47D human breast cancer cells.

MTT produces the purple color in living cells. MTT assay determine the cell
proliferation due to measuring the absorbance of purple solution at the wavelength
530nm.
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1.247

MTT assay
12
10

Effect

8
MCF-7

6

T47D

4
2
0
Day 1

Day 2

Day 3

Figure 11. MTT assay for PTIP knockdown in MCF-7 and T47D human breast cancer
cells.
After transferring siRNA-PTIP to MCF-7 and T47D human breast cancer cells,
we determined the cell proliferation of these two cell lines by MTT assay on DAY 1,
DAY 2 and DAY 3. As shown in Table 1 and Figure 11, the cell proliferation rate of
T47D didn’t show much variance, however, the cell proliferation rate of knockdown
MCF-7 cells increased relative to normal MCF-7 cells after DAY 2.
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Chapter Five
Conclusions
1.

PTIP is expressed in human breast cancer cell lines MCF-7 and T47D on both
RNA level and protein levels. The protein molecular weight of PTIP is about
120KD.

2.

The subcellular localization of PTIP in MCF-7 and T47D human breast cancer
cells is nucleus.

3.

The GFP plasmid can be transferred into MCF-7 and T47D cells at a ratio of 90%
and 70% respectively.

4.

The flag-mPTIP plasmid is not suitable for direct transfection in MCF-7 and
T47D cells.

5.

PTIP knockdown through siRNA results in an increased rate of cell proliferation
of knockdown MCF-7 cells relative to normal MCF-7 cells.

6.

Taken together, PTIP might play a suppressor role in breast cancer.
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Chapter Six
Discussion and Future Study
Discussion
During this research process, there are some unclear results the need to be
determined in the future.
The result of ectopic PTIP overexpression in human breast cancer cell lines MCF7and T47D didn’t meet our expectation. Maybe the size of the flag-mPTIP plasmid is too
large (9.2kb) to be directly transferred into breast cancer cells.
The cell proliferation rate of T47D didn’t show much variance; however, the cell
proliferation rate of knockdown MCF-7 cells increased relative to normal MCF-7 cells
after DAY 2. So PTIP may not work in all human breast cancer cell lines.

Future study
In this research, we used breast cancer cell lines MCF-7 and T47D. In future
studies, other breast cancer cell lines, such as MDA-MB-231, BT-474 and SK-BR-3, can
be tested. In addition, the primary breast cell line MCF-10 can be utilized as the control
cell line. Immunohistochemistry assay of PTIP in human breast cancer tissues and normal
breast tissues would be a good experiment to do.
PTIP has been shown to be capable of regulating histone methylation. Therefore,
whether PTIP regulates histone methylation in human breast cancer cells remains an
interesting question to be examined.
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Finding a way to transfer such a large plasmid, flag-mPTIP, into human breast
cancer cells is a significant assignment for determining the function of PTIP in breast
cancer. The virus-based transfection may be an alternative approach in future studies.
PTIP is related to histone methylation, so we can use Western blot to determine
the protein expression of histone methylation, such as H3K4me, after PTIP knockdown
and overexpression.
Apply qRT-PCR to qualify the gene PTIP in order to compare the gene
expression of PTIP in various human breast cancer cells.
The technique microarray can analyze expression level of thousand genes. So we
can use it to compare gene expression changing between PTIP control and PTIP
knockdown, or PTIP control and PTIP overexpression.
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Appendix

Figure 4. Gene expression of PTIP in MCF-7 and T47D human breast cancer cells

Figure 5. Left, protein expression of PTIP in MCF-7 and T47D human breast cancer cells;
right, protein expression of GAPDH in MCF-7 and T47D human breast cancer cells.
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MCF-7

Figure 6-1. Subcellular localization of PTIP in MCF-7 human breast cancer cells by
immunofluorescent assay
Left panel: phase contrast; middle panel: DAPI staining (blue); right panel: PTIP staining
(green).
T47D

Figure 6-2. Subcellular localization of PTIP in T47D human breast cancer cells by
immunofluorescent assay.
Left panel: phase contrast; middle panel: DAPI staining (blue); right panel: PTIP staining
(green).
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Figure 7. Gel electrophoresis of the flag-mPTIP plasmid.

Figure 8. Transfection of the GFP plasmid in MCF-7 and T47D human breast cancer
cells.
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Figure 9. Protein expression of the flag-mPTIP plasmid in MCF-7 and T47D breast
cancer cells. C, control without the flag-mPTIP plasmid; T, transfection with the flagmPTIP plasmid.
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Figure 10. Left, Protein expression of PTIP in MCF-7 human breast cancer cells; right,
protein expression of GAPDH in MCF-7 human breast cancer cells (knockdown/control).

MTT assay
12
10

Effect

8
MCF-7

6

T47D
4
2

0
Day 1

Day 2

Day 3

Figure 11. MTT assay for PTIP knockdown in MCF-7 and T47D human breast cancer
cells.
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